Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Recordati

- PMLiVE

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

Drug provided 'rapid and sustained' normalisation of mean urinary-free cortisol levels

- PMLiVE

FDA approves Recordati’s Cushing disease drug Isturisa

Important new treatment option for patients with rare disorder

- PMLiVE

Recordati acquires AstraZeneca blood pressure brands

Italian pharma firm obtains Seloken and Logimax

- PMLiVE

Recordati snaps up Swiss pharma company Pro Farma

Follows group's recent acquisition of Italian firm Italchimici

Recordati completes acquisition of Laboratorios Casen Fleet

Concludes €93m deal for Spanish gastroenterology specialist

- PMLiVE

Recordati promotes Andrea Recordati to COO

Move is part of a management reshuffle for the Italian pharma company

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

Novartis building

Novartis’ heart failure drug serelaxin meets targets

And FDA committee backs Signifor for Cushing's disease

- PMLiVE

Interview: Giovanni Recordati

The chairman and CEO of Recordati tells Linda Banks his plans for company expansion

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links